Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Novel targets being explored in multiple myeloma and the value of CELMoDs

Andrew Cowan, MD, Fred Hutchinson Cancer Center, Seattle, WA, briefly discusses novel targets being explored in multiple myeloma, including FcRH5 and CD38, and further comments on the excitement surrounding the CELMoDs iberdomide and mezigdomide. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Consulting: BMS, Adaptive
Research funding: BMS, Janssen, Adaptive, Harpoon, AbbVie, Sanofi, Nektar